A phase II trial of TAS-102 in combination with cetuximab for metastatic colorectal cancer patients
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2614887
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: TAS-102 (35 mg/m2/dose) will be administered orally BID on days1-5 and day8-12 every 28 days.
Cmab is administered once a week. The initial dose is 400 mg/m2. The subsequent weekly doses are 250 mg/m2 each.
Primary outcome(s): disease control rate
Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
创建时间：
2017-09-15
